<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01436929</url>
  </required_header>
  <id_info>
    <org_study_id>BRMH-06-2011-75</org_study_id>
    <secondary_id>BRMH-06-2011-75</secondary_id>
    <nct_id>NCT01436929</nct_id>
  </id_info>
  <brief_title>Effect of Prophylactic Use of Silymarin on Hepatotoxicity Induced by Anti-tuberculosis Drugs</brief_title>
  <acronym>PESOHHERZ</acronym>
  <official_title>Effect of Prophylactic Use of Silymarin on Hepatotoxicity Induced by Anti-tuberculosis Drugs</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seoul National University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Seoul National University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Tuberculosis is a worldwide common infectious disease and effective first line
      anti-tuberculosis (TB) drugs were available such as isoniazid, rifampicin, ethambutol, and
      pyrazinamide. However, anti-TB drugs may induce hepatic injury resulting in discontinuation
      of anti-TB drugs or changing anti-Tb drug regimen.

      Silymarin has been widely studied for the effect on hepatitis and it has been used in
      hepatology.

      Therefore, the investigators hypothesized that prophylactic administration of silymarin with
      anti-TB drugs may decrease the incidence and severity of hepatotoxicity induced by anti-TB
      drugs.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>September 2011</start_date>
  <completion_date type="Anticipated">December 2013</completion_date>
  <primary_completion_date type="Anticipated">October 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>incidence of hepatotoxicity</measure>
    <time_frame>8 weeks</time_frame>
    <description>the presence of hepatotoxicity will be evaluated at 2weeks, 4weeks, and 8weeks after initiation of anti-TB drugs. An interim analysis will be done after enrolling first 300 subjects.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>incidence of hepatotoxicity by genotypic variants</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">600</enrollment>
  <condition>Tuberculosis</condition>
  <arm_group>
    <arm_group_label>Silymarin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Silymarin: prophylactic administration of silymarin with anti-TB drugs Placebo: prophylactic administration of placebo with anti-TB drugs</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>administration of placebo with anti-TB drugs</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Silymarin</intervention_name>
    <description>Silymarin 140mg 1tab bid for 8 weeks</description>
    <arm_group_label>Silymarin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo 1tab bid</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  subjects who are diagnosed with tuberculosis based on microbiological, biomolecular,
             pathological, or radiographical findings and are expecting to be administered with
             anti-tuberculosis drugs including INH, RFP, or PZA.

          -  adults &gt;=35 years old

        Exclusion Criteria:

          -  basal AST &gt;40 IU/uL or ALT &gt;40 IU/uL

          -  pregnancy

          -  lactating women

          -  cases with history of adverse events to silymarin
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Deog Kyeom Kim, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>SMG-SNUH Bormae Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Deog Kyeom Kim, M.D.</last_name>
    <phone>82-2-870-2228</phone>
    <email>kimdkmd@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Deog Kyeom Kim</name>
      <address>
        <city>Seoul</city>
        <zip>156-707</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Deog Kyeom Kim, M.D.</last_name>
      <phone>82-2-870-2228</phone>
      <email>kimdkmd@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Chang-Hoon Lee, M.D</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Eun-young Heo, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Seo-Yoon Kim, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>December 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 16, 2011</study_first_submitted>
  <study_first_submitted_qc>September 19, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 20, 2011</study_first_posted>
  <last_update_submitted>December 13, 2012</last_update_submitted>
  <last_update_submitted_qc>December 13, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 17, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>silymarin</keyword>
  <keyword>hepatotoxicity</keyword>
  <keyword>tuberculosis</keyword>
  <keyword>HREZ</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tuberculosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Silymarin</mesh_term>
    <mesh_term>Antitubercular Agents</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

